Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus

Byron Martina, Penelopie Koraka, Petra van den Doel, Geert Amerongen, Guus Rimmelzwaan, Ab Osterhaus

Research output: Contribution to journalArticleAcademicpeer-review

58 Citations (Scopus)

Abstract

The Japanese encephalitis virus (JEV) serocomplex-group consists of mosquitoborne flaviviruses, which include West Nile virus (WNV) and JEV, and both may cause severe encephalitis in humans. WNV has spread rapidly across the United States since its introduction in 1999 and its geographical distribution within the western hemisphere is expected to further expand, whereas, JEV is the most common cause of viral encephalitis in Southeast Asia, China and India. Currently, there is no registered human vaccine or specific therapy to prevent or treat WNV infection. Here we describe the efficacy of recombinant domain III (DIII) of WNV glycoprotein E in a mouse model. It induces high neutralizing antibody titers, as well as, protection against lethal WNV infection in C57BL/6 mice. This vaccine preparation also afforded partial protection against lethal JEV infection. (c) 2007 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)153-157
Number of pages5
JournalVaccine
Volume26
Issue number2
DOIs
Publication statusPublished - 2008

Cite this